The scale of the problem is difficult to overstate. Worldwide, GBD 2023 estimates 372 million incident cases and 1.72 billion prevalent cases of MSK disorders in 2023, generating 161 million years lived with disability (YLDs), the standard metric for quantifying non-fatal health loss. Asia’s share—999 million prevalent cases and 91.6 million YLDs—translates into age-standardized rates that closely mirror global averages: an age-standardized incidence rate of 4,091.62 per 100,000 population, an age-standardized prevalence rate of 19,856 per 100,000, and an age-standardized YLDs rate of 1,828.1 per 100,000. But while age-standardized incidence in Asia actually declined slightly between 1990 and 2023, falling 8.4 percent, the absolute numbers tell a very different story. Incident cases rose 83.1 percent, prevalent cases 118 percent, and YLDs 106.3 percent over the 33-year period—growth rates that all exceeded the corresponding global increases. The divergence reflects a demographic engine that is running at full throttle: rapid population growth in South Asia and profound population aging in East Asia are multiplying case counts even as age-adjusted rates hold steady or drift downward.

The analysis disentangles six GBD-defined categories of MSK disorders: rheumatoid arthritis, osteoarthritis (OA), low back pain (LBP), neck pain, gout, and a residual group of other MSK conditions that includes systemic lupus erythematosus and axial spondyloarthritis. Each dominates a different corner of the burden landscape. Low back pain generated the most new cases in Asia in 2023—142 million—while osteoarthritis topped the prevalence ranking with 369 million existing cases. Disability burden was split between low back pain (36.87 million YLDs) and other MSK disorders (27.52 million YLDs), with osteoarthritis contributing a further 12.94 million. These distinct dominance patterns carry direct implications for health-system planning: LBP’s grip on incidence signals demand for acute primary care, early physiotherapy and recurrence prevention, whereas OA’s dominance in prevalence and its outsized economic footprint call for long-term pain management, weight-control programs and, in advanced disease, joint replacement surgery.

Perhaps the most striking epidemiological detail is the age at which low back pain strikes. Among Asian adolescents aged 10 to 14, LBP accounted for 87.5 percent of all MSK incident cases—the highest proportion of any age group. The authors link this to the region’s intense academic pressures and prolonged sedentary time in schools, where adjustable furniture and backpack-weight limits are rarely implemented. Overall, MSK disorders affected every age group except children under five, with incident cases, prevalent cases and YLDs peaking in the 50-to-59 age bracket for both sexes. Rates themselves rose with age, peaked at 75 to 84 years, and then declined—with one telling exception. Gout, unlike every other MSK category, showed incidence, prevalence and YLDs that climbed continuously with age, with no late-life plateau.

Sex differences were equally pronounced. For all MSK disorders except gout, the burden was higher in women than in men, a pattern the researchers attribute to hormonal factors such as post-menopausal bone loss, the higher prevalence of rheumatoid arthritis and osteoarthritis among women, and the concentration of female workers in labor-intensive agricultural and garment-sector jobs across lower-income Asian countries. Georgia recorded the highest female-to-male ratios for prevalent cases (1.88) and YLDs (1.98), while India showed the largest gender gap in incident cases, also at 1.88. Conversely, in several Gulf states—the United Arab Emirates, Qatar, Bahrain, Oman, Saudi Arabia and Kuwait—and the Maldives, the ratios dipped below 1, meaning men carried a somewhat heavier burden.

Geographically, the continent is far from uniform. East Asia carried the largest absolute burden, followed by South Asia, Southeast Asia, Western Asia and Central Asia. Yet when rates were age-standardized, the ordering inverted: Western Asia recorded the highest incidence (9,745.3 per 100,000), prevalence (40,426.62 per 100,000) and YLDs rates (3,873.61 per 100,000), while East Asia posted the lowest. At the country level, China, India, Indonesia and Japan bore the heaviest absolute caseloads, while Japan (5,741.99 per 100,000), Iran and Israel reported the highest age-standardized incidence rates. Temporal trajectories diverged sharply as well: Qatar’s incident cases in 2023 were 7.82 times its 1990 figure, and the United Arab Emirates saw prevalent cases explode by 924.4 percent, while Georgia was the lone country recording declines across the board. Israel stood out as the only nation with a negative estimated annual percentage change in age-standardized prevalence.

The study also probes why. Using the population-attributable fraction method, the team quantified how much disability could theoretically be prevented by reducing exposure to four modifiable risk factors: occupational ergonomic stressors, smoking, high body mass index (BMI) and kidney dysfunction. High BMI emerged as the fastest-growing threat, with BMI-attributable YLDs rising in all 47 countries—up 301 percent in India, 190 percent in Vietnam and 148 percent in Timor-Leste since 1990. Kuwait recorded the highest current proportion of BMI-attributable burden at 15.95 percent of MSK YLDs. Occupational ergonomic factors dominated in Central and Southeast Asia, peaking in Georgia (10.77 percent), while smoking’s contribution was concentrated in East and West Asia, led by Lebanon at 9.48 percent. Kidney dysfunction, though the smallest contributor overall (0.19 percent globally), was most prominent in Malaysia. The researchers suggest the BMI trajectory in developing Asia parallels the obesity epidemics that swept Latin America in the 1990s and 2000s, driven by nutrition transition and urbanization.

The economic dimension of the analysis is its most novel contribution. Because GBD does not directly report healthcare spending, the team extrapolated from United States per-patient expenditure data for 2019, adjusting for each country’s total health spending relative to that of the US and expressing results in inflation-adjusted dollars. The resulting model estimates global direct medical costs of MSK disorders at roughly $751.2 billion in 2023, of which Asia accounted for $419.6 billion—about 0.55 percent of regional GDP and 55.9 percent of the global total. Osteoarthritis was the costliest single condition in Asia at approximately $88.8 billion, ahead of low back pain ($66.2 billion), neck pain ($49.0 billion) and rheumatoid arthritis ($29.7 billion), with gout cheapest at $2.5 billion. East Asia shouldered $342.4 billion of the regional total, led by China at $320.98 billion, while Bhutan, Timor-Leste and Brunei combined for a mere $96,000 under the model. The authors caution that lower labor costs, lower uptake of expensive procedures and drug-price differences in low- and middle-income countries mean their Asia figure is likely an upper bound. Still, the chronic nature of OA and the price of joint replacement in aging societies such as China and Japan explain why the condition, though less incident than back pain, dominates the ledger—and why early conservative management could yield substantial savings.

Correlation analysis with the socio-demographic index (SDI), a composite measure of income, education and fertility, added another layer of nuance. Osteoarthritis rates correlated strongly and positively with SDI (Spearman coefficients of 0.74 to 0.77), reflecting the aging affluence of high-income societies, while total MSK rates showed only weak-to-moderate associations. The authors translate these gradients into differentiated policy prescriptions: high-SDI settings such as Japan and China should prioritize tertiary orthopedic capacity, joint replacement access and geriatric care including fall prevention, whereas low-SDI settings in South and Southeast Asia should focus on primary prevention—community weight-loss programs, workplace ergonomics in manufacturing and agriculture, and school-based posture education. Specific proposals include adjustable desks and backpack-weight limits for Asian schools, early OA management pathways in aging nations, and obesity strategies featuring tools such as sugar-sweetened beverage taxes in high-burden countries like Kuwait and India.

The team is candid about limitations. Data completeness varies across the continent, particularly in Central and South Asia; the GBD framework lacks quality-of-life data beyond YLDs; evolving diagnostic technologies and coding practices over 33 years may compromise comparability; and as a secondary descriptive analysis, the study identifies associations rather than causal mechanisms. The economic figures, built on a macro-level extrapolation, are order-of-magnitude estimates rather than precise accounting. Even so, the study marks a milestone: the first to integrate disease burden, risk attribution and modeled economic cost across the whole of Asia using GBD 2023 data, at a moment when low back pain has climbed into the top ten causes of global disability. With a billion Asians already living with musculoskeletal disease and obesity rising across the developing half of the continent, the authors argue that the window for affordable prevention is narrowing. What happens in Asian classrooms, workplaces and clinics over the coming decade will shape the disability profile of more than half of humanity.

Musculoskeletal disorders encompass a broad spectrum of conditions including osteoarthritis, rheumatoid arthritis, gout, osteoporosis, and chronic back pain, which collectively rank among the primary causes of disability worldwide. The study aimed to dissect the contribution of population aging to the rising incidence of these conditions, disentangling it from other demographic variables such as population growth, and epidemiological factors including age-specific incidence rate changes. This nuanced approach allowed researchers to assess how shifts in demographic structures directly translate into healthcare burden and costs on a global scale.

The investigators utilized the Global Burden of Disease (GBD) 2021 database—an unparalleled repository of health metrics—and applied sophisticated statistical methods to separate three intertwined influences: population growth, aging, and changes in disease-specific epidemiology. By doing so, they illuminated previously obscured trends showing that population aging alone is responsible for a significant portion of the increased burden of musculoskeletal disorders in roughly one-third of countries analyzed. This finding underscores aging not merely as a correlating factor but as a principal driver in certain geopolitical and socioeconomic contexts.

A particularly striking result is the disproportionate impact observed in middle-income countries. Although these countries generally possess younger populations than high-income nations, the rapid pace of demographic aging exacerbates their musculoskeletal disease burden. The health systems in these regions often lack the necessary infrastructure and resources to manage the complex needs of an aging population afflicted by chronic, disabling conditions. This mismatch predicts escalating challenges for healthcare delivery and social support systems unless preemptive public health strategies are implemented.

Sex-specific analyses revealed critical disparities in how population aging affects men and women globally. Men in high- and upper-middle income countries exhibit a greater increase in musculoskeletal disorder burden attributable to aging, whereas women in low- to middle-income nations bear a relatively higher impact. These variations likely reflect differences in occupational exposures, lifestyle factors, healthcare access, and biological susceptibilities, demanding tailored interventions that consider gender alongside socioeconomic status.

Among the various musculoskeletal conditions studied, osteoarthritis emerged as the most significantly influenced by population aging worldwide, followed by gout and rheumatoid arthritis. The progressive wear and tear characteristic of osteoarthritis, coupled with the immune-mediated inflammation seen in rheumatoid arthritis, highlights the multifactorial nature of these diseases and the importance of integrating demographic trends with pathophysiological understanding in healthcare planning.

The economic ramifications detailed in the study are profound. Population aging-related musculoskeletal disorders accounted for an estimated US$96 billion in global healthcare expenditures in 2021 alone. This figure corresponds to approximately 0.10% of the global gross domestic product (GDP), overtaking the financial burdens linked to commonly modifiable risk factors such as smoking, obesity, and physical inactivity. These costs encompass direct medical treatment, long-term care, rehabilitation, and indirect costs stemming from disability and lost productivity.

Dr. Hai-Feng Pan, the study’s lead investigator, emphasized the heterogeneous nature of population aging’s impact on musculoskeletal health. According to Dr. Pan, middle-income countries face not only rapidly aging populations but also a lack of preparedness in their healthcare infrastructures. “Our findings highlight the urgent need for health systems in these regions to build capacity and resilience geared towards the unique challenges posed by aging-related disorders,” he stated, advocating for policy reforms and investment in geriatric musculoskeletal health.

Co-lead investigator Dr. Shi-Yang Guan further elaborated on the policy implications, stressing how the results equip policymakers with the evidence necessary to design interventions finely tuned to sociodemographic realities and disease-specific burdens. He envisions a multipronged approach that bolsters preventive measures, improves disease management, and ensures sustainable financing to mitigate burgeoning costs and improve patient outcomes. Guan advocates for changing the way aging populations are served by public health systems globally, with a concerted focus on musculoskeletal health.

The importance of a global perspective on these findings is echoed by Professor Lyn March, a renowned authority in musculoskeletal epidemiology. She stressed that musculoskeletal health issues represent a colossal and growing challenge, urgently necessitating global strategies to address the physical, emotional, and economic toll of these conditions. “Without concentrated effort, societies will grapple increasingly with loss of mobility, chronic pain, and diminished quality of life among billions,” Professor March warned, reinforcing the call for immediate and sustained action.

Editor-in-Chief of the Annals of the Rheumatic Diseases, Dr. Josef Smolen, underlined the critical need for intensified research and innovation targeting musculoskeletal disorders within the context of aging populations, especially in the European Union and globally. He posited that an integrated research agenda, combining epidemiological insights with advances in treatment and prevention, is pivotal to attaining healthful aging and reducing the enormous personal and societal burdens generated by these diseases.

Methodologically, the study capitalized on advanced demographic modeling and epidemiological analysis, leveraging detailed age-stratified incidence data and economic modeling techniques. This approach provided unprecedented granularity, enabling the attribution of disease burden and costs to specific demographic factors rather than crude population metrics. The integration of such data is anticipated to reshape public health priorities and orient healthcare delivery towards upstream demographic determinants.

In summary, this groundbreaking research reframes the narrative around musculoskeletal disorders, shifting attention toward the demographic drivers of disease burden and the imperative for health systems worldwide to adapt accordingly. By quantifying the undeniable role of population aging in increasing global musculoskeletal disease incidence and costs, it sets the foundation for informed, equitable, and sustainable healthcare policies directed at one of the most universal but underappreciated dimensions of public health.

As populations continue to age dynamically around the world, this study serves as a clarion call to health professionals, researchers, policymakers, and communities to unite in addressing the multifaceted challenges posed by musculoskeletal disorders. The findings provide a roadmap for proactive strategies that not only confront the rising tide of disability and economic strain but also enhance quality of life and functional independence for aging individuals globally.

Subject of Research: People

Article Title: The impact of population ageing on musculoskeletal disorders in 204 countries and territories, 1990-2021: global burden and healthcare costs

News Publication Date: 16-Sep-2025

Web References:
https://doi.org/10.1016/j.ard.2025.08.002
https://ard.eular.org/

References: Guan et al., Annals of the Rheumatic Diseases, 2025; Global Burden of Disease 2021 dataset

Image Credits: Annals of the Rheumatic Diseases / Guan et al.

Keywords: population aging, musculoskeletal disorders, osteoarthritis, rheumatoid arthritis, gout, global health burden, healthcare costs, epidemiology, demographic transitions, disability, health economics